We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Lab-on-a-Chip Technology Breaks New Bioparticle Separation Record

By LabMedica International staff writers
Posted on 23 Aug 2016
Print article
Image: The nano-DLD chip (2 cm x 2 cm) mounted in a microfluidic jig. The technology allows a liquid sample to be passed, in continuous flow, through a silicon chip containing an asymmetric pillar array that allows sorting a microscopic waterfall of nanoparticles, separating particles by size down to 20 nanometer resolution (Photo courtesy of IBM Research).
Image: The nano-DLD chip (2 cm x 2 cm) mounted in a microfluidic jig. The technology allows a liquid sample to be passed, in continuous flow, through a silicon chip containing an asymmetric pillar array that allows sorting a microscopic waterfall of nanoparticles, separating particles by size down to 20 nanometer resolution (Photo courtesy of IBM Research).
Scientists have developed a new lab-on-a-chip technology that can, for the first time, separate biological particles at the nanoscale down to 20 nanometers in diameter, a scale that gives access to important particles such as DNA, viruses, and exosomes. The breakthrough could enable detection of various diseases before symptoms appear and would facilitate use of relatively noninvasive liquid biopsies.

The device was developed by a team led by scientists from IBM Thomas J Watson Research Center (Yorktown Heights, NY, USA). Once separated, these particles can be analyzed to potentially reveal signs of disease even before patients experience physical symptoms and when the outcome from treatment is most positive. Until now, the smallest bioparticle that could be separated by size with on-chip technologies was about 50 times or larger, for example, separation of circulating tumor cells from other biological components. The study results also showed that separation can take place despite diffusion, a hallmark of particle dynamics at these small scales.

IBM Research partnered with the Icahn School of Medicine at Mount Sinai (NY, USA) to develop exosome-based liquid biopsies using IBM’s nano technology, and will continue the collaboration to further develop this lab-on-a-chip and to test it on prostate cancer.

In precision medicine, exosomes are increasingly being viewed as valuable biomarkers to help reveal the origin and nature of a cancer and for diagnosis and prognosis of malignant tumors. Exosomes are released in easily accessible bodily fluids such as blood, saliva, or urine. The IBM team targeted exosomes with their lab-on-chip technology due to the challenges facing existing techniques for separating and purifying exosomes in liquid biopsies. Exosomes range in size from 20-14 nm and contain information about the health of the originating cell that they are shed from. A determination of the size, surface proteins, and nucleic acid cargo carried by exosomes can give essential information about the presence and state of developing cancer and other diseases. With Mount Sinai, IBM hopes to confirm their technology can pick up exosomes with cancer-specific biomarkers from patient liquid biopsies.

“The ability to sort and enrich biomarkers at the nanoscale in chip-based technologies opens the door to understanding diseases such as cancer as well as viruses like the flu or Zika,” said Gustavo Stolovitzky, program director, Translational Systems Biology and Nanobiotechnology, IBM Research.

With the ability to sort bioparticles at the nanoscale, Mount Sinai hopes that IBM’s technology can provide a new method to eavesdrop on cell-to-cell messages carried by exosomes, to monitor this intercellular conversation. “When we are ahead of the disease we usually can address it well; but if the disease is ahead of us, the journey is usually much more difficult. One of the important developments that we are attempting in this collaboration is to have the basic grounds to identify exosome signatures that can be there very early on before symptoms appear or before a disease becomes worse,” said Carlos Cordon-Cardo, MD, PhD, Mount Sinai Health System, and Icahn School of Medicine, “By bringing together Mount Sinai’s domain expertise in cancer and pathology with IBM’s systems biology experience and its latest nanoscale separation technology, the hope is to look for specific, sensitive biomarkers in exosomes.”

Using a technology called nanoscale deterministic lateral displacement, or nano-DLD, IBM scientists Joshua Smith and Benjamin Wunsch led development of a lab-on-a-chip technology that allows a liquid sample to be passed, in continuous flow, through a silicon chip containing an asymmetric pillar array. This array allows the system to sort a microscopic waterfall of nanoparticles, separating particles by size down to resolution of 10s of nanometers. IBM has already scaled down the chip size to 2cm by 2cm, while continuing development to increase the technology density to improve functionality and throughput. Leveraging IBM’s vast semiconductor expertise with its growing capabilities in experimental biology, the scientists used manufacturable silicon processes to produce the nano-DLD arrays for their lab-on-a-chip technology.

Much like how a road through a small tunnel only allows smaller cars to pass while forcing bigger trucks to detour around, nano-DLD uses a set of pillars to deflect larger particles while allowing smaller particles to flow through the gaps of the pillar array unabated, effectively separating this particle traffic by size while not disrupting flow. The scientists noticed that nano-DLD arrays can also split a mixture of many different particle sizes into a spread of streams, somewhat like a prism splits white light into different colors. The continuous flow nature of this technology circumvents stop-and-go batch processing typical of conventional separation techniques.

The study, by Wunsch BH et al, was published online August 1, 2016, in the journal Nature Nanotechnology.

Related Links:
IBM Thomas J Watson Research Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.